ZL006 is a PSD95-nNOS protein-protein interaction inhibitor. ZL006 (EC50: 12.88 M) directly inhibited binding of purified PSD95 and nNOS proteins in AlphaScreen without altering binding of PSD95 to ErbB4. ZL006 preferentially suppressed phase 2A pain behavior in the formalin test and suppressed allodynia induced by intraplantar complete Freund's adjuvant administration. Disrupting PSD95-nNOS protein-protein interactions is effective in attenuating pathological pain without producing unwanted side effects (i.e. motor ataxia) associated with NMDAR antagonists.
仅供研究使用。 我们不向患者出售。
化学信息
名称 | ZL006 |
Iupac 化学名称 | ZL006 |
同义词 | ZL006; ZL-006; ZL 006 |
英文同义词 | ZL006; ZL-006; ZL 006 |
分子式 | C14H11Cl2NO4 |
分子量 | 328.145 |
Smile | c1cc(c(cc1NCc2cc(cc(c2O)Cl)Cl)O)C(=O)O |
InChiKey | RTEYSQSXRFVKTJ-UHFFFAOYSA-N |
InChi | InChI=1S/C14H11Cl2NO4/c15-8-3-7(13(19)11(16)4-8)6-17-9-1-2-10(14(20)21)12(18)5-9/h1-5,17-19H,6H2,(H,20,21) |
Cas号 | 1181226-02-7 |
MDL | MFCD20527326 |
相关CAS号 | |
外观性状 | crystalline solid |
纯度 | 98% |
存储 | 3 years -20ºCpowder |
可溶性 | Soluble in DMSO |
处理方式 | |
运输条件 | Shipped under ambient temperature as non-hazardous chemical. |
海关编码 | |
Targets | |
Mechanism | |
Cell study | |
Animal study | |
Clinical study | |